Nonmyeloablative stem cell transplantation (NST) has been evaluated in patients with chronic lymphocytic leukaemia (CLL). 1 Such conditioning regimens frequently lead to a state of mixed chimerism in which donor-and host-derived haematopoiesis coexist for a prolonged period post transplant. 2 Bethge and co-workers recently reported on their experience of the use of donor lymphocyte infusion (DLI) in 53 of 446 patients who had received transplants from HLA-matched related or unrelated donors after conditioning with 2 Gy total body irradiation (TBI) with or without fludarabine. 3 In their protocol, patients were eligible for DLI once all immunosuppression had been discontinued without any flare of graft-versus-host disease (GvHD) for at least 3 weeks. Autoimmune haemolytic anaemia (AIHA) is a common complication of CLL with a reported incidence of 4-40% during the course of the disease. 4 Control in severe cases may require protracted systemic immunosuppression.
We report a case of refractory AIHA post-NST for CLL, which necessitated maintenance oral corticosteroids. Due to persistent disease in the context of mixed T-cell chimerism and the absence of GvHD, DLI was administered to the patient who remained on systemic immunosuppression. Conversion to full donor chimerism ensued and disease regression was noted.
A 41-year-old man presented with fatigue, pallor and jaundice in 1997 and was diagnosed with CLL complicated by AIHA. The Direct Antiglobulin Test (DAT) was positive. He was treated with corticosteroids and subsequently went on to receive six cycles of chlorambucil (20 mg ) from day À4 to day À2 inclusive and TBI (2 Gy) on day 0. 5.04 Â 10 6 G-CSFmobilised CD34 þ cells/kg were infused. Post-graft immunosuppression consisted of mycophenolate mofetil (MMF) 15 mg/kg p.o. twice daily from day 0 until day þ 28 and cyclosporin A (CSA) 5 mg/kg p.o. twice daily from day À1, which was to be tapered through day þ 180.
His post-NST course was complicated by recurrence of AIHA (DAT þ ve for IgG and C3d), which necessitated treatment with prednisolone (1 mg/kg) on day þ 93. Both the prednisolone and cyclosporin were then tapered and the cyclosporin was stopped on day þ 152. Shortly thereafter, however, worsening haemolysis required the reintroduction of cyclosporin and high-dose corticosteroids. Although a second attempt to stop cyclosporin was successful by day þ 318, protracted AIHA prevented reduction of the prednisolone dose below 20 mg/day.
Serial chimerism results are shown in Figure 1 . His persistent mixed chimeric state was attributed in part to the ongoing need for immunosuppression. In an attempt to target the autoreactive B-cell clone responsible for the AIHA, rituximab (375 mg/m 2 ) was infused weekly for 4 weeks from day þ 365. He nonetheless remained dependent on prednisolone, and mixed chimerism persisted (43% donor on day þ 398). Simultaneous lineage-specific T-cell (CD3 þ ) chimerism revealed 91% donor status. The decision was therefore made to proceed to DLI and he received 1.1 Â 10 7 CD3 þ cells/kg on day þ 465. Despite recrudescence of haemolysis immediately after the DLI and the consequent need to increase once again the dose of prednisolone to 1 mg/kg, donor chimerism had risen to 96% on day þ 508, 99% on day þ 550 and 100% on day þ 613. When most recently assessed on day þ 902, Hb was 13.1 g/dl, WCC 8.8 Â 10 9 /l, neutrophils 6.8 Â 10 9 /l and platelets 288 Â 10 9 /l. His DAT remains positive for IgG and weakly positive for C3d. The dose of prednisolone has been further tapered to 10 mg/day and he remains a full donor chimera.
NST provides a platform after which the judicious use of either additional immunoreactive donor T cells or further immunosuppression will allow for stable engraftment while minimising the risk of GvHD. 2 In a study of the kinetics of engraftment after NST, Baron et al 5 noted that while none of 40 patients conditioned with 2 Gy TBI and fludarabine prior to sibling transplantation experienced graft rejection, most remained mixed chimeras for up to 180 days. DLI has been advocated to convert stable mixed chimerism into full donor chimerism and thereby eliminate residual disease. 3 The complete withdrawal of immunosuppression is generally considered a prerequisite to DLI to allow for the full graft-versus-tumour (GvT) effect from the engrafted T cells and to thereby minimise the need for DLI and the associated risk of GvHD. In this case, the AIHA had proven refractory to rituximab despite promising reports of its use in this context. 6, 7 It was therefore decided to proceed to DLI with the patient continuing to receive systemic corticosteroids, as the presence of mixed T-cell chimerism suggested the potential for a GvT effect, conversion to full donor chimerism and elimination of the presumed residual autoreactive host lymphocytes responsible for the AIHA. Despite continued immunosuppression, he converted to full donor chimerism 5 months later, disease regression has been noted and no GvHD has been seen. He is currently receiving the lowest dose of prednisolone he has tolerated since reactivation of AIHA on day þ 93.
It therefore appears that in the rare circumstances of a refractory autoimmune process post-NST, systemic immunosuppression should not be considered an absolute contraindication to the successful use of DLI in the context of mixed chimerism and persistent disease.
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